molecular-biology-heart-congress-2018-keynote

3 / 5

Page 7
allied
academies
Journal of Biomedical Research | Volume: 29
4th World Heart Congress
Molecular Biology, Tissue Science and Regenerative Medicine
International Conference on
Joint Event
&
November 19-20, 2018 | Paris, France
The late adverse effects of pelvic radiotherapy concern 5 to
10% of them, which could be life threatening. However, a
clear medical consensus concerning the clinical management
of such healthy tissue sequelae does not exist. Our group has
demonstrated in preclinical animal models that systemic MSC
injection is a promise approach for the medical management of
gastrointestinal disorder after irradiation. We have shown that
MSCmigrate to damaged tissues and restore gut functions after
irradiation.
The clinical status of four first patients suffering from
severe pelvic side effects resulting from an over-dosage
was improved following MSC injection in a compassional
situation. A quantity of 2x106 - 6x106 MSC/kg were infused
intravenously to the patients. Pain, hemorrhage, frequency
of diarrhoeas and fistulisation as well as the lymphocyte
subsets in peripheral blood were evaluated before MSC
therapy and during the follow-up. Two patients revealed a
substantiated clinical response for pain and haemorrhage
after MSC therapy. In one patient pain reappeared after 6
months and again substantially responded on a second MSC
infusion. A beginning fistulisation process could be stopped
in one patient resulting in a stable remission for more than
3 years of follow-up. The frequency of painful diarrhea
diminished from an average of 6/d to 3/d after the first and
2/d after the 2nd MSC injection in one patient. In all patients,
prostate cancer remained in stable complete remission. A
modulation of the lymphocyte subsets towards a regulatory
pattern and diminution of activated T cells accompanies the
clinical response in refractory irradiation-induced colitis. No
toxicity occurred.
MSCtherapywassafeandeffectiveonpain,diarrhea,haemorrhage,
inflammation, fibrosis and limited fistulisation. For patients with
refractory chronic inflammatory and fistulising bowel diseases,
systemicMSCinjectionsrepresentasafeoptionforsalvagetherapy.
Aclinical phase II trialwill start in2018.
Speaker Biography
Alain Chapel has been developing gene and cell therapy using non-human primates,
immune-tolerant mice and rats to protect against the side effects of radiation. He
collaborates with clinicians to develop strategies for treatment of patients after
radiotherapy overexposures. He has participated in the first establishment of proof of
concept of the therapeutic efficacy of mesenchymal stem cells (MSCs) for the treatment
of hematopoietic deficit, radiodermatitis and over dosages of radiotherapy. He has
contributed to the first reported correction of deficient hematopoiesis in patients
(graft failure and aplastic anemia) thanks to intravenous injection of MSCs restoring the
bone marrow microenvironment, mandatory to sustain hematopoiesis after total body
irradiation. He is scientific investigator of clinical phase II trial evaluating the efficacy of
systemic MSC injections for the treatment of severe and chronic radiotherapy-induced
abdomino-pelvic complications refractory to standard therapy.
e:
Alain Chapel
Institute of Radiological Protection and Nuclear Safety, France
Stem cell therapy for the treatment of severe tissue damage after radiation exposure
Alain Chapel, Molecular Biology & Heart Congress 2018, Volume 29
DOI: 10.4066/biomedicalresearch-C8-021